- Home
- LXEH vs MAIA Comparison
LXEH vs MAIA Comparison
Compare LXEH & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXEH | MAIA |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 44.9M |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | LXEH | MAIA |
|---|---|---|
| Price | $0.32 | $1.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 236.5K | ★ 454.0K |
| Earning Date | 12-30-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,585,942.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.30 | $0.87 |
| 52 Week High | $50.08 | $2.74 |
Technical Indicators
Market Signals| Indicator | LXEH | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 30.81 | 53.94 |
| Support Level | $0.31 | $1.07 |
| Resistance Level | $0.37 | $1.25 |
| Average True Range (ATR) | 0.03 | 0.12 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 18.36 | 55.93 |
Price Performance
Historical ComparisonAbout LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.